AMGEN INC

Amgen shares slip 2% on July 9, 2026 while Nasdaq climbs, amid FDA approval of a new oncology biosimilar that could reshape the biotech race.

Amgen’s 3.55% rally on July 2 shows biotech resilience: strong earnings, a growing therapeutic pipeline, and a 52‑week high within reach—investors eye continued upside.

Amgen’s latest investor outreach, market positioning and collaborative drug trials highlight its biotech leadership and AI‑driven innovation potential.

Amgen’s biotech strategy fuels growth—expanding biologics, scaling manufacturing, and advancing clinical trials to strengthen market leadership and investor confidence.

Amgen’s blend of blockbuster drugs and AI‑driven ADC innovation positions it for growth in oncology and precision medicine.

Amgen’s Q4 earnings beat expectations, driving the stock to a 52‑week high and a $350 target as institutional buying surges.

Amgen’s $1.4 billion oncology acquisition spree signals a bold push toward cancer therapies, promising pipeline growth amid a biotech boom and investor optimism.

Amgen’s 2025 earnings and pipeline fuel a bullish outlook, with oncology and chronic disease growth, analyst upgrades, and strong R&D discipline driving investor confidence.

Amgen’s biotech edge: how its robust R&D, precision‑medicine pipeline and scalable manufacturing position it to lead the booming recombinant antibody and protein market.

Amgen’s new U.S. drug‑price plan and the launch of denosumab biosimilars reveal how the company balances cost cuts with innovation—boosting its market edge and shareholder value.